Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) SVP Jason B. Daly sold 43,657 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Amneal Pharmaceuticals Trading Up 1.3 %
Shares of NASDAQ:AMRX opened at $8.44 on Wednesday. The stock's fifty day simple moving average is $8.58 and its two-hundred day simple moving average is $7.70. Amneal Pharmaceuticals, Inc. has a 1-year low of $4.16 and a 1-year high of $9.48. The stock has a market cap of $2.61 billion, a PE ratio of -12.41 and a beta of 1.17.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Several large investors have recently made changes to their positions in AMRX. Hennessy Advisors Inc. purchased a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $8,818,000. Rubric Capital Management LP increased its position in shares of Amneal Pharmaceuticals by 12.4% during the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company's stock valued at $68,083,000 after purchasing an additional 1,179,830 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Amneal Pharmaceuticals by 701.8% during the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company's stock valued at $5,148,000 after purchasing an additional 710,598 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Amneal Pharmaceuticals by 114.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company's stock valued at $10,026,000 after purchasing an additional 642,065 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company's stock valued at $27,205,000 after purchasing an additional 641,405 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold | Ad
Trump's back in the White House, but Wall Street is pissed.
Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.
AMRX has been the topic of a number of recent research reports. Piper Sandler increased their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 target price on the stock in a report on Friday, September 6th. Barclays raised their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a research note on Tuesday, August 13th. Finally, StockNews.com upgraded Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $10.00.
Check Out Our Latest Analysis on Amneal Pharmaceuticals
Amneal Pharmaceuticals Company Profile
(
Get Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
